美国临床肿瘤学会多基因检测临床实践指南更新及临床意义

doi:10.6040/j.issn.1671-7554.0.2017.1074

摘要/Abstract

摘要： 近年来,随着多基因检测在早期浸润性乳腺癌患者辅助化疗决策中的使用,早期浸润性乳腺癌的综合诊治理念已在细化解剖学分期,精确掌握宏观肿瘤负荷的基础上,跨越到结合基因检测信息、分析肿瘤生物学特性,实施个体化治疗以达到损伤最小化的新阶段。2017年7月《临床肿瘤学杂志》(Journal of Clinical Oncology, JCO)刊登美国临床肿瘤学会(American Society of Clinical Oncology, ASCO)多基因检测临床指南更新内容,其中,针对不同人群多基因检测提出推荐意见,重点提高了MammaPrint^®临床应用的推荐强度,旨在科学指导临床医生合理地制定治疗决策,避免过度医疗。

关键词: 乳腺癌, 美国临床肿瘤学会, 多基因检测, MammaPrint^®,

Abstract: In recent years, multigene tests have been recommended to guide decisions on the need of adjuvant chemotherapy for patients with early-stage breast cancer. The comprehensive strategy of early-stage breast cancer has come into an era, when both anatomic tumor burden and multigene test results should be taken into consideration to gain a better understanding of tumor biology and personalized treatment, in order to minimize toxic effects. In July 2017, the Journal of Clinical Oncology(JCO)published the new version of the clinical practice guideline of American Society of Clinical 山东大学学报 (医学版)56卷1期 -刘荫华,等.美国临床肿瘤学会多基因检测临床实践指南更新及临床意义 \=-Oncology(ASCO)on the use of biomarkers to guide therapeutic decision for breast cancer. The guideline provided criteria of clinical utility for different patient groups, and focused on the recommendation of MammaPrint^®with evidence of high quality, leading to reasonable decision-making for clinicians to avoid overtreatment.

Key words: Breast cancer, American Society of Clinical Oncology, Multigene tests, MammaPrint^®,

中图分类号:

R737.9

刘荫华,赵婧祎,辛灵. 美国临床肿瘤学会多基因检测临床实践指南更新及临床意义[J]. 山东大学学报 (医学版), 2018, 56(1): 1-5.

LIU Yinhua, ZHAO Jingyi, XIN Ling. Focused updates of American Society of Clinical Oncology Guideline on the use of multigene tests in clinical practice for breast cancer[J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 1-5.

参考文献

[1] Krop I, Ismaila N, Andre F, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update[J]. J Clin Oncol, 2017, 35(24): 2838-2847.
[2] Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2015, 26(Suppl~5): 8-30.
[3] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: breast cancer. V.2.2017. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
[4] Liedtk C, Thil M, Jackisch C, et al. AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2017[J]. Breast Care, 2017, 12(3): 172-183.
[5] vant Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer[J]. Nature, 2002, 415(6871): 530-536.
[6] van de Vijver MJ, He YD, vant Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer[J]. N Engl J Med, 2002, 347: 1999-2009.
[7] Buyse M, Loi S, vant Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer[J]. J Natl Cancer Inst, 2006, 98(17): 1183-1192.
[8] Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J]. Annals of Oncol, 2011, 22(8): 1736-1747.
[9] Bogaerts J, Cardoso F, Buyse M, et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial[J]. Nat Clin Pract Oncol, 2006, 3(10): 540-551.
[10] Cardoso F, Vant Veer L, Rutgers E, et al. Clinical application of the 70-gene profile: the MINDACT trial[J]. J Clin Oncol, 2008, 26(5): 729-735.
[11] Cardoso F, vant Veer LJ, Bogaerts J, et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer[J]. N Engl J Med, 2016, 375(8): 717-729.
[12] Adjuvant! Online Web Site. http://www.adjuvantonline.com.
[13] Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual[M]. 8th ed. New York: Springer, 2016.
[14] Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer[J]. J Clin Oncol, 2001, 19(4): 980-991.
[15] Mook S, Schmidt MK, Rutgers EJ, et al. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study[J]. Lancet Oncol, 2009, 10(11): 1070-1076.
[16] Hajage D, de Rycke Y, Bollet M, et al. External validation of Adjuvant! Online breast cancer prognosis tool. Prioritising recommendations for improvement[J]. PLoS One, 2011, 6(11): e27446. doi: 10.1371/journal.pone.0027446. Epub 2011 Nov 8.
[17] Campbell HE, Taylor MA, Harris AL, et al. An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom[J]. Br J Cancer, 2009, 101(7): 1074-1084.
[18] Olivotto IA, Bajdik CD, Ravdin PM, et al. Population based validation of the prognostic model ADJUVANT! for early breast cancer[J]. J Clin Oncol, 2005, 23(12): 2716-2725.
[19] Users Guide for Adjuvant! Version 8.0, Dec 2005.
[20] Duffy MJ, Harbeck N, Nap M, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers(EGTM)[J]. Eur J Cancer, 2017, 75: 284-298. doi: 10.1016/j.ejca.2017.01.017. Epub 2017 Feb 28.
[21] Oncotype DX^® Web Site. http://www.oncotypedx.com.
[22] EndoPredict^® Web Site.http://www.endopredict.com/en/home.html.
[23] Prosigna^®, PAM 50 Web Site. https://www.nanostring.com/diagnostics/prosigna.
[24] Breast Cancer Index Web Site. https://www.breastcancerindex.com.
[25] 江泽飞, 许凤锐. 乳腺癌精准医学: 热潮中的冷思考[J]. 中华外科杂志, 2017, 55(2): 90-94. JIANG Zefei, XU Fengrui. Calm thinking for precision medicine of breast cancer in the boom[J]. Chinese Journal of Surgery, 2017, 55(2): 90-94.

相关文章 15

[1]	林芸,谢燕秋. 乳腺癌患者生育力保护及保存[J]. 山东大学学报 (医学版), 2022, 60(9): 42-46.
[2]	贺士卿,李皖皖,董书晴,牟婧怡,刘宇莹,魏思雨,刘钊,张家新. 基于数据库构建乳腺癌焦亡相关基因的预后风险模型[J]. 山东大学学报 (医学版), 2022, 60(8): 34-43.
[3]	杨其峰,张宁. 精准医疗时代的乳腺癌前哨淋巴结活检[J]. 山东大学学报 (医学版), 2022, 60(8): 1-5.
[4]	李涛,杨春林,杜通,李亨,王聪聪,李晓丽,段瑞生,张蓬. 糖尿病对重症肌无力NK细胞亚型及功能的影响[J]. 山东大学学报 (医学版), 2022, 60(5): 31-36.
[5]	赵婷婷,齐亚娜,张颖,袁冰,韩明勇. 小鼠乳腺癌诱导转移前肺组织微环境的改变[J]. 山东大学学报 (医学版), 2022, 60(4): 24-29.
[6]	李鸿皓,于晶,陈亚丽,郭守刚. 20例NMOSD患者CD4⁺CD25⁺FoxP3⁺调节性T细胞数量和FoxP3 mRNA的表达水平[J]. 山东大学学报 (医学版), 2022, 60(4): 50-54.
[7]	初竹秀,赵文静,李小燕,孔晓丽,马婷婷,江立玉,杨其峰. 218例女性乳腺癌患者行新辅助化疗及伴随分子标志物改变的临床价值[J]. 山东大学学报 (医学版), 2021, 59(9): 130-139.
[8]	王喆,刘玉洁,毛倩,管佩霞,包绮晗,李承圣,乔晓伟,潘庆忠,王素珍. 基于逆概率加权法的早期三阴性乳腺癌不同治疗方案的疗效评价[J]. 山东大学学报 (医学版), 2021, 59(8): 113-118.
[9]	李皖皖,周文凯,董书晴,贺士卿,刘钊,张家新,刘斌. 利用数据库信息构建乳腺癌免疫关联lncRNAs风险评估模型[J]. 山东大学学报 (医学版), 2021, 59(7): 74-84.
[10]	孔雪,李娟,段伟丽,史爽,李培龙,杜鲁涛,毛海婷,王传新. 长链非编码RNA AC012073.1对乳腺癌细胞迁移侵袭的影响及临床价值[J]. 山东大学学报 (医学版), 2021, 59(4): 70-78.
[11]	李湘青,殷欣,赵雪莲,赵培庆. NK细胞亚群CD56^bright在帕金森患者外周血中的表达及临床意义[J]. 山东大学学报 (医学版), 2021, 59(2): 34-40.
[12]	隋荣翠,韩书慧,张宪昭,范新泰,王娜,侯凌霄,许安廷. 小鼠内淋巴囊原代上皮细胞L型钙离子通道定位表达[J]. 山东大学学报 (医学版), 2021, 59(10): 17-22.
[13]	高奎,万广宁,宋晓鹏,信波. 吡咯替尼治疗曲妥珠耐药HER2阳性乳腺癌1例[J]. 山东大学学报 (医学版), 2020, 58(12): 117-120.
[14]	王丹鹤,方文岩,张艳萍. 放射性¹²⁵I粒子治疗肺腺癌伴沉默性骨骼肌转移瘤1例[J]. 山东大学学报 (医学版), 2020, 58(11): 118-120.
[15]	林琦,张颖,袁苑,戴建建,徐瑞彩,杨琦,耿宝成,韩明勇. 肾上腺转移瘤放射性¹²⁵I粒子植入治疗后胃穿孔1例[J]. 山东大学学报（医学版）, 2017, 55(7): 124-129.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed